MX2017008505A - Composicion. - Google Patents
Composicion.Info
- Publication number
- MX2017008505A MX2017008505A MX2017008505A MX2017008505A MX2017008505A MX 2017008505 A MX2017008505 A MX 2017008505A MX 2017008505 A MX2017008505 A MX 2017008505A MX 2017008505 A MX2017008505 A MX 2017008505A MX 2017008505 A MX2017008505 A MX 2017008505A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- sequence
- composition
- amino acid
- present
- Prior art date
Links
- 102000003911 Thyrotropin Receptors Human genes 0.000 abstract 2
- 108090000253 Thyrotropin Receptors Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023328 Basedow disease Diseases 0.000 abstract 1
- 208000015023 Graves' disease Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/05—Animals modified by non-integrating nucleic acids, e.g. antisense, RNAi, morpholino, episomal vector, for non-therapeutic purpose
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención provee una composición que comprende los siguientes péptidos del receptor de hormona estimulante de la tiroides (TSHR): (i) toda o parte de la secuencia de aminoácidos KKKKYVSIDVTLQQLESH KKK (SEQ ID NO: 1), o una parte de la misma, o una secuencia que tiene por lo menos 60% de identidad de secuencia con SEQ ID NO: 1; y (ii) toda o parte de la secuencia de aminoácidos GLKMFPDLTKVYSTD (SEQ ID NO: 2), o una parte de la misma, o una secuencia que tiene al menos 60% de identidad de secuencia con SEQ ID NO: 2. La presente invención también se refiere al uso de dicha composición para la prevención o supresión de la activación de formación de autoanticuerpo en la enfermedad de Graves.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201423171 | 2014-12-24 | ||
| GBGB1520190.8A GB201520190D0 (en) | 2015-11-16 | 2015-11-16 | Composition |
| GBGB1520199.9A GB201520199D0 (en) | 2015-11-16 | 2015-11-16 | Composition |
| GBGB1520196.5A GB201520196D0 (en) | 2015-11-16 | 2015-11-16 | Composition |
| PCT/IB2015/059942 WO2016103213A1 (en) | 2014-12-24 | 2015-12-23 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017008505A true MX2017008505A (es) | 2018-03-07 |
Family
ID=55135475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008505A MX2017008505A (es) | 2014-12-24 | 2015-12-23 | Composicion. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10646589B2 (es) |
| EP (1) | EP3236746B1 (es) |
| JP (2) | JP7117847B2 (es) |
| KR (1) | KR102585625B1 (es) |
| CN (1) | CN107249617A (es) |
| AU (2) | AU2015370415B2 (es) |
| CA (1) | CA2971995A1 (es) |
| ES (1) | ES2996234T3 (es) |
| HU (1) | HUE070090T2 (es) |
| IL (1) | IL252977B (es) |
| MX (1) | MX2017008505A (es) |
| PL (1) | PL3236746T3 (es) |
| RU (1) | RU2728963C2 (es) |
| SG (1) | SG11201705020VA (es) |
| WO (1) | WO2016103213A1 (es) |
| ZA (1) | ZA201704464B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3385168B2 (ja) | 1996-10-31 | 2003-03-10 | 三菱電機株式会社 | 自動プログラミング装置 |
| WO2018127828A1 (en) * | 2017-01-04 | 2018-07-12 | Apitope International Nv | Therapeutic method using tolerogenic peptides |
| EP3360884A1 (en) * | 2017-02-10 | 2018-08-15 | Neuronax | Improved process for the preparation of a dodecapeptide |
| EP3622962A1 (en) * | 2018-09-14 | 2020-03-18 | advanceCOR GmbH | Short cyclic peptides for the treatment of graves' disease |
| CN114601913B (zh) * | 2022-03-09 | 2025-03-04 | 陕西慧普德泰生物科技有限责任公司 | 人TSHR A亚基在预防Graves病中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0652764B1 (en) | 1992-02-10 | 2000-05-24 | Duke University | Use of synthetic peptides to induce tolerance to pathogenic t and b cell epitopes of autoantigens |
| DK1311542T3 (da) * | 2000-08-21 | 2008-11-10 | Apitope Technology Bristol Ltd | Tolerogene peptider |
| ES2736165T3 (es) * | 2001-08-23 | 2019-12-26 | Rsr Ltd | Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas |
| GB0202399D0 (en) | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| WO2007057778A2 (en) | 2005-11-21 | 2007-05-24 | Dr. Fenning Biomed Gmbh | Recombinant polypeptides and methods for detecting and/or quantifying autoantibodies against tsh receptor |
| GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| GB201314444D0 (en) | 2013-08-13 | 2013-09-25 | Maher Ltd | Method for hip can manufaturing and can |
-
2015
- 2015-12-23 CN CN201580076154.1A patent/CN107249617A/zh active Pending
- 2015-12-23 JP JP2017534205A patent/JP7117847B2/ja active Active
- 2015-12-23 AU AU2015370415A patent/AU2015370415B2/en active Active
- 2015-12-23 SG SG11201705020VA patent/SG11201705020VA/en unknown
- 2015-12-23 WO PCT/IB2015/059942 patent/WO2016103213A1/en not_active Ceased
- 2015-12-23 RU RU2017126212A patent/RU2728963C2/ru active
- 2015-12-23 KR KR1020177018598A patent/KR102585625B1/ko active Active
- 2015-12-23 HU HUE15823811A patent/HUE070090T2/hu unknown
- 2015-12-23 CA CA2971995A patent/CA2971995A1/en active Pending
- 2015-12-23 US US15/537,577 patent/US10646589B2/en active Active
- 2015-12-23 EP EP15823811.3A patent/EP3236746B1/en active Active
- 2015-12-23 ES ES15823811T patent/ES2996234T3/es active Active
- 2015-12-23 MX MX2017008505A patent/MX2017008505A/es unknown
- 2015-12-23 PL PL15823811.3T patent/PL3236746T3/pl unknown
-
2017
- 2017-06-18 IL IL252977A patent/IL252977B/en unknown
- 2017-06-30 ZA ZA2017/04464A patent/ZA201704464B/en unknown
-
2020
- 2020-10-16 JP JP2020174899A patent/JP2021020927A/ja active Pending
-
2022
- 2022-05-12 AU AU2022203198A patent/AU2022203198B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201704464B (en) | 2020-10-28 |
| AU2015370415A1 (en) | 2017-07-13 |
| RU2020116871A3 (es) | 2021-02-19 |
| CN107249617A (zh) | 2017-10-13 |
| JP2018502093A (ja) | 2018-01-25 |
| EP3236746C0 (en) | 2024-11-27 |
| IL252977B (en) | 2022-06-01 |
| EP3236746B1 (en) | 2024-11-27 |
| RU2017126212A3 (es) | 2019-06-19 |
| EP3236746A1 (en) | 2017-11-01 |
| ES2996234T3 (en) | 2025-02-12 |
| HUE070090T2 (hu) | 2025-05-28 |
| PL3236746T3 (pl) | 2025-03-31 |
| SG11201705020VA (en) | 2017-07-28 |
| NZ732987A (en) | 2022-03-25 |
| JP2021020927A (ja) | 2021-02-18 |
| AU2022203198A1 (en) | 2022-06-02 |
| AU2022203198B2 (en) | 2025-04-03 |
| CA2971995A1 (en) | 2016-06-30 |
| US10646589B2 (en) | 2020-05-12 |
| WO2016103213A1 (en) | 2016-06-30 |
| KR20170095922A (ko) | 2017-08-23 |
| US20180264139A1 (en) | 2018-09-20 |
| IL252977A0 (en) | 2017-08-31 |
| JP7117847B2 (ja) | 2022-08-15 |
| KR102585625B1 (ko) | 2023-10-05 |
| RU2020116871A (ru) | 2020-08-31 |
| AU2015370415B2 (en) | 2022-06-02 |
| RU2017126212A (ru) | 2019-01-24 |
| RU2728963C2 (ru) | 2020-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| NZ731571A (en) | T cell receptors | |
| AU2017248121A1 (en) | T cell receptors | |
| AU2017248120A1 (en) | T cell receptors | |
| MX393988B (es) | Variantes de interferon a2b. | |
| NZ737796A (en) | Anti-tau antibodies and methods of use | |
| MX357505B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| NZ715038A (en) | T cell receptors | |
| MX2017008505A (es) | Composicion. | |
| MX384984B (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| PH12013500715A1 (en) | Anticancer fusion protein | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| PH12016500218A1 (en) | Peptides | |
| ZA202109182B (en) | Natriuretic peptide receptor 1 antibodies and methods of use | |
| MY209410A (en) | Recombinant protein variants | |
| WO2015107363A3 (en) | Mycobacterial antigen composition | |
| MY193807A (en) | T-cell receptor and uses thereof | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| NZ738990A (en) | Cgrp receptor antagonists | |
| NZ729514A (en) | Therapeutic multi-peptides t specific immune therapy for treatment of brain metastasis | |
| MX2016011852A (es) | Composiciones y metodos para prevenir o tratar la disfuncion cronica del aloinjerto pulmonar (clad) y fibrosis pulmonar idiopatica (fpi). | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| EP3925968A3 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
| EA201690966A1 (ru) | Новое соединение для лечения тяжелой гипогликемии |